A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs PDC APB (Primary)
- Indications Contact dermatitis
- Focus Adverse reactions; First in man
- Sponsors Hapten Sciences
- 21 Feb 2018 Status changed from recruiting to completed.
- 18 Jan 2017 Time frame of primary endpoint has changed from 14 days to 24 weeks.
- 18 Jan 2017 Planned End Date changed from 1 Aug 2016 to 1 Oct 2017.